DENODO
2.6.2024 14:31:31 CEST | Business Wire | Press release
Denodo, a leader in data management is opening their new Middle East regional head office in Riyadh, Kingdom of Saudi Arabia (KSA) today. To inaugurate the office opening, Denodo is launching their first “Denodo Data Day” with Her Highness Dr. Shaikha Dheya Bint Ebrahim Al Khalifa and delegates from Google Cloud, among others, as guest speakers. The new office will support new and existing Denodo customers and partners in the Middle East, providing them with direct access to the company’s experts in logical data management and AI-supported data solutions. This regional expansion is a testament to Denodo’s growing business and its customers in the region.
"We are thrilled to expand our presence in the Middle East with the opening of our new office in Riyadh, a city known for its rapid growth and innovation," said Ángel Viña, CEO and founder at Denodo. "Riyadh is host to a growing number of companies and government agencies, particularly in the technology, finance, and energy sectors – including the ambitious NEOM City. This new office will enable us to better serve our customers in the Middle East, providing them with our 'fearless data' approach to logical data management and the cutting-edge solutions they need to stay ahead in today's competitive market."
Denodo has made significant investments in AI and GenAI, which supports the Kingdom’s Vision 2030’s AI goals of making Saudi Arabia an international AI hub. Saudi Arabia is investing heavily in AI to diversify its economy. PwC recently published estimates that AI will contribute more than $135 billion to Saudi Arabia’s economy by 2030, which would lessen its reliance on revenue from oil. The Kingdom’s National Strategy aims for a global AI ranking of 15 by 2030. Recently, Saudi Arabia gained the top spot for AI government strategy. However, data management remains a hurdle. Traditional methods are complex and slow, hindering businesses seeking AI's potential in areas like customer experience.
“Saudi Arabia is the largest economy in the Middle East, and it’s going through an amazing period of growth and change,” said Gabriele Obino, regional vice president and general manager, Middle East, Denodo. “Denodo is a pioneer in logical data management, and we are offering local and regional organizations, in various industries including aviation, healthcare and Government, the opportunity to start or continue their digital transformations to modern cloud and GenAI-based data solutions.”
By fostering strong collaboration with key technology providers and systems integrators, such as the global cloud hyperscaler Google Cloud, Denodo demonstrates that its customers in the Middle East have access to the most innovative and comprehensive data solutions available, empowering them to make informed, data-driven decisions to help them stay ahead in today's competitive landscape.
Niall McDonagh, director, EMEA Public Sector, Google Cloud, emphasized the unique position of Google Cloud in Saudi Arabia: “As the only cloud provider with a dedicated region in Saudi Arabia, Google Cloud is uniquely positioned to support the digital transformation needs of this vibrant market. Our partnership with Denodo for the inaugural Denodo Data Day in Riyadh is a pivotal moment for us to showcase how our cloud solutions, coupled with Denodo’s logical data management technology, can drive significant advancements in key industries such as finance, healthcare, government, and education. We are also excited to highlight the capabilities of our Google Cloud Center of Excellence, which provides strategic guidance and cloud technology expertise.”
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602513059/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom